1. COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects. (29th May 2016) Authors: Hu, Xiao; Shang, Shulian; Nestorov, Ivan; Hasan, Jawad; Seddighzadeh, Ali; Dawson, Katherine; Sperling, Bjørn; Werneburg, Brian Journal: British journal of clinical pharmacology Issue: Volume 82:Number 2(2016:Aug.) Page Start: 380 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. (March 2022) Authors: Pittock, Sean J; Fujihara, Kazuo; Palace, Jacqueline; Berthele, Achim; Kim, Ho Jin; Oreja-Guevara, Celia; Nakashima, Ichiro; Levy, Michael; Shang, Shulian; Yountz, Marcus; Miller, Larisa; Armstrong, Róisín; Wingerchuk, Dean M Journal: Multiple sclerosis Issue: Volume 28:Number 3(2022) Page Start: 480 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Long-Term Eculizumab in AQP4+ NMOSD: Relapse-Risk Reduction and Safety in PREVENT and its Completed Open-Label Extension. (5th December 2022) Authors: Berthele, Achim; Wingerchuk, Dean; Fujihara, Kazuo; Palace, Jacqueline; Levy, Michael; Kim, Ho Jin; Nakashima, Ichiro; Oreja-Guevara, Celia; Wang, Kai-Chen; Shang, Shulian; Yountz, Marcus; Pittock, Sean Journal: Neurology Issue: Volume 99:Number 23(2022)Supplement 2 Page Start: S3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Long-Term Eculizumab in AQP4+ NMOSD: Relapse-Risk Reduction and Safety in PREVENT and its Completed Open-Label Extension. (5th December 2022) Authors: Berthele, Achim; Wingerchuk, Dean; Fujihara, Kazuo; Palace, Jacqueline; Levy, Michael; Kim, Ho Jin; Nakashima, Ichiro; Oreja-Guevara, Celia; Wang, Kai-Chen; Shang, Shulian; Yountz, Marcus; Pittock, Sean Journal: Neurology Issue: Volume 99:Number 23(2022)Supplement 2 Page Start: S3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Long-Term Eculizumab in AQP4+ NMOSD: Relapse-Risk Reduction and Safety in PREVENT and its Completed Open-Label Extension. (5th December 2022) Authors: Berthele, Achim; Wingerchuk, Dean; Fujihara, Kazuo; Palace, Jacqueline; Levy, Michael; Kim, Ho Jin; Nakashima, Ichiro; Oreja-Guevara, Celia; Wang, Kai-Chen; Shang, Shulian; Yountz, Marcus; Pittock, Sean Journal: Neurology Issue: Volume 99:Number 23(2022)Supplement 2 Page Start: S3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN. (August 2018) Authors: Newsome, Scott D.; Scott, Thomas F.; Arnold, Douglas L.; Nelles, Gereon; Hung, Serena; Cui, Yue; Shang, Shulian; Naylor, Maria L.; Kremenchutzky, Marcelo Journal: Therapeutic advances in neurological disorders Issue: Volume 11(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD. Issue 6 (27th February 2021) Authors: Wingerchuk, Dean M.; Fujihara, Kazuo; Palace, Jacqueline; Berthele, Achim; Levy, Michael; Kim, Ho Jin; Nakashima, Ichiro; Oreja‐Guevara, Celia; Wang, Kai‐Chen; Miller, Larisa; Shang, Shulian; Sabatella, Guido; Yountz, Marcus; Pittock, Sean J. Other Names: Villa Andres investigator.; Garcea Orlando investigator.; Manin Analisa investigator.; Melamud Luciana investigator.; Aguirre Florencia investigator.; Fernandez Victoria investigator.; Muñoz Daniel Julio investigator.; Amor Jorge investigator.; Bocchiardo Carolina investigator.; Obregon Carolina ... Journal: Annals of neurology Issue: Volume 89:Issue 6(2021) Page Start: 1088 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis. (August 2018) Authors: Arnold, Douglas L.; Shang, Shulian; Dong, Qunming; Meergans, Matthias; Naylor, Maria L. Journal: Therapeutic advances in neurological disorders Issue: Volume 11(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Sample Size Calculation for Controlling False Discovery Proportion. (16th August 2012) Authors: Shang, Shulian; Zhou, Qianhe; Liu, Mengling; Shao, Yongzhao Other Names: Zhang Xiaohua Douglas Academic Editor. Journal: Journal of probability and statistics Issue: Volume 2012(2012) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. (January 2017) Authors: Cadavid, Diego; Cohen, Jeffrey A; Freedman, Mark S; Goldman, Myla D; Hartung, Hans-Peter; Havrdova, Eva; Jeffery, Douglas; Kapoor, Raj; Miller, Aaron; Sellebjerg, Finn; Kinch, Deborah; Lee, Sophia; Shang, Shulian; Mikol, Daniel Journal: Multiple sclerosis Issue: Volume 23:Number 1(2017) Page Start: 94 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗